Definium Therapeutics (DFTX) Income towards Parent Company (2019 - 2026)

Definium Therapeutics (DFTX) has 8 years of Income towards Parent Company data on file, last reported at -$57.0 million in Q1 2026.

• Quarterly Income towards Parent Company fell 87.82% year-over-year to -$57.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$187.5 million (down 80.3% YoY) and the FY2025 annual result came in at -$160.8 million, down 69.96% from the prior year.
• Income towards Parent Company slipped to -$57.0 million in Q1 2026 per DFTX's latest filing, from -$45.4 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at $56.9 million in Q4 2022 and bottomed at -$57.0 million in Q1 2026.
• The 5-year median for Income towards Parent Company is -$21.8 million (2024), against an average of -$23.3 million.
• The widest annual swing landed in 2022, when Income towards Parent Company surged 104.95%; it then plunged 137.83% in 2023.
• Tracing DFTX's Income towards Parent Company over 5 years: stood at $56.9 million in 2022, then tumbled by 137.83% to -$21.5 million in 2023, then plunged by 38.72% to -$29.8 million in 2024, then sank by 52.06% to -$45.4 million in 2025, then decreased by 25.54% to -$57.0 million in 2026.
• Per Business Quant, the three latest DFTX Income towards Parent Company figures stand at -$57.0 million (Q1 2026), -$45.4 million (Q4 2025), and -$44.7 million (Q3 2025).

Peer Comparison